Introduction
Prostate apoptosis response-4 (Par-4) is a proapoptotic protein identi®ed in a screen for genes induced during apoptosis (Sells et al., 1994 Rangnekar, 1998) . The par-4 gene shows widespread expression in diverse tissue types and is exclusively induced by apoptotic stimuli but not by growth promoting, growth arresting, or necrotic stimuli Sells et al., 1994; Rangnekar, 1998) . Functional studies have indicated that Par-4 is required but not sucient to cause apoptosis in prostatic and non-prostatic cell culture models Diaz-Meco et al., 1996) . Consistent with these observations, Par-4 serves to sensitize cells to the action of apoptotic insults DiazMeco et al., 1996) . Recent studies have suggested that Par-4 causes apoptosis by a p53-independent mechanism that may involve inhibition of protein kinase C-z and mitogen-activated protein kinase function and activation of p38 kinase (Berra et al., 1997) . Moreover, overexpression of Par-4 causes down-regulation of Bcl-2 in ®broblasts and prostate cancer cells, and replenishment of Bcl-2 levels rescues the cells from the pro-apoptotic eects of Par-4 (Qiu et al., 1998) . These observations suggest that Par-4 acts to sensitize cells to apoptosis by inhibiting cell survival functions. Evidence for an in vivo role for Par-4 protein comes from our recent ®nding that Par-4 levels are increased in neuronal degeneration in Alzheimers' patients and the demonstration that Par-4 is necessary for neuronal apoptosis in cell culture paradigms relevant to the pathogenesis of Alzheimer's disease (Guo et al., 1998) .
Renal cell carcinoma (RCC) is the most common form of kidney cancer, aecting about 27 000 individuals in the United States each year with a high rate of mortality . Chemotherapy and radiotherapy work poorly for RCC, and immunotherapy has only limited success. Thus, the disease spreads rapidly within a median survival of less than one year. RCCs may arise owing to von HippelLindau (VHL) disease, a neoplastic disorder manifested by tumors of the kidney and other organs (Maher et al., 1990) or sporadically, i.e., by non-VHL associated mechanisms. Mutation of the tumor suppressor VHL gene is associated with all VHL-associated RCCs and in a majority (70%) of sporadic RCCs (Chen et al., 1995; Crossey et al., 1994; Foster et al., 1994; Gnarra et al., 1994; Illiopoulos et al., 1995) . Conceptually, apoptotic proteins may confer anti-oncogenic functions and prevent the process of malignant transformation (Williams, 1991; Wyllie, 1992; Kerr et al., 1994; Pan et al., 1997) . We considered the possibility that Par-4 may be down-regulated in human tumors. When normal and cancerous tissues from at least 25 patients each with pathologically con®rmed neuroblastomas, prostate cancers, head and neck tumors, or RCCs were examined for Par-4 expression, only the RCCs showed decreased Par-4 protein levels relative to the corresponding normal cells. We describe here the decreased expression of Par-4 in RCC tumors and primary cell cultures, and the eect of replenishment of Par-4 levels on sensitivity to apoptosis. Our ®ndings suggest that decreased expression of Par-4 in RCCs conferred diminished sensitivity to apoptosis.
Results and discussion
We examined whether par-4 was dierentially expressed in normal tubular cells and clear cell type of RCCs. A total of 27 tumors derived from RCC patients were subjected either to hematoxylin and eosin staining to identify the normal and cancerous areas or to immunohistochemistry with anti-Par-4 or pre-immune antibody. The proximal renal tubular (PRT) cells and glomeruli from the normal areas within all of the 27 tumors stained positive for Par-4 expression (Table 1) . On the other hand, only 7 out of the 27 clear cell carcinoma specimens showed staining for Par-4 in the cancerous areas of the tumor. The (Table 1 and Figure 1 ). The absence of Par-4 protein in the cancerous areas was not restricted to tumors from any particular grade of the disease (Table 1) . These ®ndings suggested that Par-4 protein levels were decreased in cancerous areas of the RCCs relative to the PRT cells. We ascertained that the cancerous areas in the RCCs showed quantitatively lower amounts of Par-4 protein relative to the normal areas. The cancerous and normal areas from a total of 10 dierent clear cell tumors were separated by micro-dissection, and protein extracts prepared from the tissues were subjected to Western blot analysis for Par-4 or b-actin for a loading control. A majority of the tumors showed very low to undetectable levels of Par-4 in cancerous areas of the tumors relative to the normal areas (Figure 1f) . However, in 20% of the tumors, the cancerous areas showed Par-4 protein amounts that were comparable to those in the normal areas from the same tumor (Figure 1f ). Thus, par-4 expression is quantitatively down-regulated in RCCs.
Because clear cell carcinomas are believed to be derived from PRT cells, we examined par-4 expression in primary cell cultures of clear cell type of RCC or PRT that were derived and established from RCC tumors (Walther et al., 1995) . A total of six PRT cultures and 22 RCC (clear cell carcinoma) primary cell lines were examined for Par-4 expression by Western blot analysis. The PRT cell lines showed consistently high levels of Par-4 protein (representative levels shown in Figure 2a , left panel). On the other hand, the RCC cell lines could be categorized into three types (I, II, III), depending on the relative expression levels of Par-4 (Figure 2a, left panel) . Only two of the RCC cell lines showed a high level of Par-4 expression (type III) that was 10 ± 20% lower than that seen in PRT cell lines. By contrast, 13 cell lines showed about 60% lower amounts (type II) and seven cell lines showed 80 ± 90% lower amounts (type I) of Par-4 relative to the PRT cell lines. These ®ndings suggest that a majority of the RCC cell lines showed lower amounts of Par-4 protein relative to PRT cell lines, consistent with the observations from the RCC tumors.
We next examined the eect of Par-4 levels in RCC cell lines on sensitivity to apoptosis-producing agents. Primary cell lines established from two dierent RCC tumors that expressed about 80% lower levels of Par-4 compared to the PRT cells were transfected with either the vector or the CMV/Par-4 expression construct. Stably transfected clones were selected and pools of about 100 transfected clones were maintained as cell lines. Expression of Par-4 in the dierent pools that contained CMV/Par-4 or vector alone was examined by Western blot analysis. The ®ndings were similar for the two dierent primary cell lines and data for one of the lines Pp are shown in Figure 2 . The pools arising from cells transfected with CMV/Par-4 expressed 3 ± 4-fold higher levels of Par-4 protein relative to those from cells transfected with vector (Figure 2a ; right panel). The transfected cell lines were then examined for susceptibility to the apoptosis-producing agents doxorubicin or tumor necrosis factor-a (TNF-a) by terminal transferase dUTP-nick end labeling (TUNEL). Doxorubicin caused a dose-dependent increase in apoptosis, with a signi®cantly higher number of TUNEL-positive cells (P50.0001 by Students t-test) in transfectants expressing the CMV/ Par-4 construct relative to those expressing vector alone (Figure 2b ). Sensitization to TNF-a was relatively stronger in transfectants containing CMV/ Par-4 : transfectants containing the vector showed 52% apoptosis at concentrations of 25 or 50 ng/ml and 510% apoptosis at 100 ng/ml of TNF-a; by contrast, transfectants containing CMV/Par-4 showed a dose-dependent increase in apoptosis beginning at 25 ng/ml of TNF-a (Figure 2b ). These ®ndings suggest construct, and about 100 transfected clones were pooled to obtain cell lines. Whole-cell protein extracts were prepared from pooled transfectants (P1 or P2) and 20 mg amounts of extract proteins were subjected to Western blot analysis for Par-4. (b) An increase in Par-4 levels enhances sensitivity to apoptosis. Pp/vector.P1 and Pp/CMV/Par-4.P1 transfectants were exposed to the indicated amounts of doxorubicin or TNF-a for 96 h and tested for apoptosis by TUNEL. About 400 cells were scored for TUNELpositive nuclei in each experiment to quantify apoptosis. TUNEL results shown are a mean of three separate experiments; error bars indicate+standard deviation that replenishment of Par-4 levels enhanced the sensitivity of RCC cell lines to apoptotic agents. As neither doxorubicin nor TNF-a induced Par-4 in the Pp cells (data not shown), the apoptosis caused by these agents in the vector transfected Pp cells that express low levels of endogenous Par-4 (see Figure 2b ) may be mediated by a Par-4-independent pathway.
The identi®cation of diminished expression of par-4 in a majority of RCCs or RCC cell lines relative to normal renal tubular cells within tumors or PRT cell lines, respectively, is a novel feature of this study. Reintroduction of par-4 in RCC cells resulted in enhanced susceptibility to apoptosis-producing agents. These ®ndings suggest that decreased expression of Par-4 in renal cell carcinoma may confer diminished susceptibility to apoptosis. Because malignant transformation or progression is inhibited by pro-apoptotic proteins (Williams, 1991; Wyllie, 1992; Kerr et al., 1994; Pan et al., 1997) , decreased expression of Par-4 may result in loss of anti-oncogenic functions and contribute to the patho-physiology of RCC. This hypothesis needs to be tested directly in appropriate cell culture and in vivo paradigms.
Materials and methods

Cell culture and chemicals
PRT and RCC cells from tumors were derived and established in cultures as described previously (Walther et al., 1995) . Doxorubicin was purchased from Sigma Chemical Co., St Louis, MO, USA and TNF-a was from R & D Systems, Minneapolis, MN, USA.
Immunohistochemical analysis of archival specimens
Freshly frozen paran-embedded RCC tissue containing both normal and tumor areas was sectioned and subjected to immunohistochemical analysis with the anti-Par-4 antibody (R334) or a pre-immune antibody as described previously . The sections were also stained with hematoxylin and eosin to examine tissue topology.
Western blot analysis for Par-4
Protein extracts from micro-dissected RCC tissues or from cell cultures were prepared and 20 mg amounts were subjected to Western blot analysis with a 1 : 1000 dilution of the anti-Par-4 antibody (R334) or an anti-actin antibody (Sigma Chemical Co.), as described previously . All signals were quanti®ed by scanning densitometry, then normalized with respect to the corresponding signal for actin, and expressed as fold induction relative to the signal in the control lane.
Transfection and quanti®cation of apoptotic cells
RCC cell lines were transfected either with empty vector pCB6+ or CMV/Par-4 expression construct as described , and stably transfected clones were selected by using G418 sulfate (400 mg/ml). About 100 individual clones were pooled and maintained as transfected cell lines. Cultures of cells treated with apoptotic agents were subjected to in situ quanti®cation of apoptosis by TUNEL by using the ApopTag kit (from Oncor Inc, Gaithersburg, MD, USA.) as described .
